Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) CFO Pamela Ann Connealy purchased 88,850 shares of the business's stock in a transaction that occurred on Tuesday, November 26th. The stock was bought at an average price of $1.96 per share, with a total value of $174,146.00. Following the completion of the purchase, the chief financial officer now owns 1,199,143 shares of the company's stock, valued at $2,350,320.28. This trade represents a 8.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Pyxis Oncology Stock Up 3.4 %
PYXS opened at $1.83 on Thursday. Pyxis Oncology, Inc. has a twelve month low of $1.48 and a twelve month high of $6.85. The company has a fifty day moving average of $3.54 and a 200-day moving average of $3.56. The stock has a market cap of $108.83 million, a PE ratio of -1.78 and a beta of 1.27.
Analysts Set New Price Targets
A number of research analysts recently commented on PYXS shares. Stifel Nicolaus assumed coverage on Pyxis Oncology in a research note on Thursday, August 8th. They issued a "buy" rating and a $10.00 price target for the company. William Blair lowered Pyxis Oncology from an "outperform" rating to a "market perform" rating in a research note on Thursday, November 21st. Stephens initiated coverage on shares of Pyxis Oncology in a research report on Friday, November 8th. They set an "overweight" rating and a $13.00 target price on the stock. Royal Bank of Canada upped their price target on shares of Pyxis Oncology from $7.00 to $10.00 and gave the company an "outperform" rating in a research report on Thursday, November 21st. Finally, HC Wainwright reiterated a "buy" rating and set a $7.00 price target on shares of Pyxis Oncology in a report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $10.00.
Media Is Mocking Elon, But Wait Until They See This Demo
From Brownstone Research | Ad
Elon Musk believes his new AI product will be worth an incredible $9 trillion.
But the mainstream media is not buying it.
Click here to watch this demo and decide for yourself.
View Our Latest Analysis on PYXS
Institutional Trading of Pyxis Oncology
A number of large investors have recently bought and sold shares of the business. Ikarian Capital LLC acquired a new position in shares of Pyxis Oncology in the 1st quarter valued at about $7,082,000. Vanguard Group Inc. lifted its stake in Pyxis Oncology by 7.3% in the first quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company's stock valued at $5,970,000 after buying an additional 94,740 shares during the period. Millennium Management LLC boosted its holdings in shares of Pyxis Oncology by 125.3% during the 2nd quarter. Millennium Management LLC now owns 1,336,908 shares of the company's stock worth $4,425,000 after buying an additional 743,499 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Pyxis Oncology by 5.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company's stock worth $3,982,000 after buying an additional 57,016 shares during the period. Finally, Blue Owl Capital Holdings LP acquired a new position in shares of Pyxis Oncology during the 2nd quarter valued at $3,462,000. 39.09% of the stock is currently owned by institutional investors and hedge funds.
About Pyxis Oncology
(
Get Free Report)
Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
